Plerixafor Plus Granulocyte Colony-Stimulating Factor for Patients with Non-Hodgkin Lymphoma and Multiple Myeloma: Long-Term Follow-Up Report

Ivana N. Micallef, Patrick J. Stiff, Auayporn P. Nademanee, Richard Maziarz, Mitchell E. Horwitz, Edward A. Stadtmauer, Jonathan L. Kaufman, John M. McCarty, Rita Vargo, Peter D. Cheverton, Martin Struijs, Brian Bolwell, John F. DiPersio

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

The purpose of this report is to analyze long-term clinical outcomes of patients exposed to plerixafor plus granulocyte colony-stimulating factor (G-CSF) for stem cell mobilization. This was a study of patients with non-Hodgkin lymphoma (NHL; n = 167) and multiple myeloma (MM; n = 163) who were enrolled in the long-term follow-up of 2 pivotal phase III studies (NCT00741325 and NCT00741780) of 240 µg/kg plerixafor plus 10 µg/kg G-CSF, or placebo plus 10 µg/kg G-CSF to mobilize and collect CD34+ cells for autologous hematopoietic stem cell transplantation. Overall survival (OS) and progression-free survival (PFS) were evaluated over a 5-year period following the first dose of plerixafor or placebo. The probability of OS was not significantly different in patients with NHL or MM treated with plerixafor or placebo (NHL: 64%; 95% confidence interval [CI], 56% to 71% versus 56%; 95% CI, 44% to 67%, respectively; MM: 64%; 95% CI, 54% to 72% versus 64%; 95% CI, 53% to 73%, respectively). In addition, there was no statistically significant difference in the probability of PFS over 5 years between treatment groups in patients with NHL (50%; 95% CI, 44% to 67% for plerixafor versus 43%; 95% CI, 31% to 54% for placebo) or those with MM (17%; 95% CI, 10% to 24% for plerixafor versus 30%; 95% CI, 21% to 40% for placebo). In this long-term follow-up study, the addition of plerixafor to G-CSF for stem cell mobilization did not affect 5-year survival in patients with NHL or patients with MM.

Original languageEnglish (US)
JournalBiology of Blood and Marrow Transplantation
DOIs
StateAccepted/In press - Jan 1 2018

Fingerprint

Granulocyte Colony-Stimulating Factor
Multiple Myeloma
Non-Hodgkin's Lymphoma
Confidence Intervals
Placebos
Hematopoietic Stem Cell Mobilization
Disease-Free Survival
Survival
JM 3100
Hematopoietic Stem Cell Transplantation

Keywords

  • Long-term follow-up
  • Multiple myeloma
  • Non-Hodgkin lymphoma
  • Plerixafor
  • Stem cell mobilization

ASJC Scopus subject areas

  • Hematology
  • Transplantation

Cite this

Plerixafor Plus Granulocyte Colony-Stimulating Factor for Patients with Non-Hodgkin Lymphoma and Multiple Myeloma : Long-Term Follow-Up Report. / Micallef, Ivana N.; Stiff, Patrick J.; Nademanee, Auayporn P.; Maziarz, Richard; Horwitz, Mitchell E.; Stadtmauer, Edward A.; Kaufman, Jonathan L.; McCarty, John M.; Vargo, Rita; Cheverton, Peter D.; Struijs, Martin; Bolwell, Brian; DiPersio, John F.

In: Biology of Blood and Marrow Transplantation, 01.01.2018.

Research output: Contribution to journalArticle

Micallef, IN, Stiff, PJ, Nademanee, AP, Maziarz, R, Horwitz, ME, Stadtmauer, EA, Kaufman, JL, McCarty, JM, Vargo, R, Cheverton, PD, Struijs, M, Bolwell, B & DiPersio, JF 2018, 'Plerixafor Plus Granulocyte Colony-Stimulating Factor for Patients with Non-Hodgkin Lymphoma and Multiple Myeloma: Long-Term Follow-Up Report', Biology of Blood and Marrow Transplantation. https://doi.org/10.1016/j.bbmt.2018.01.039
Micallef, Ivana N. ; Stiff, Patrick J. ; Nademanee, Auayporn P. ; Maziarz, Richard ; Horwitz, Mitchell E. ; Stadtmauer, Edward A. ; Kaufman, Jonathan L. ; McCarty, John M. ; Vargo, Rita ; Cheverton, Peter D. ; Struijs, Martin ; Bolwell, Brian ; DiPersio, John F. / Plerixafor Plus Granulocyte Colony-Stimulating Factor for Patients with Non-Hodgkin Lymphoma and Multiple Myeloma : Long-Term Follow-Up Report. In: Biology of Blood and Marrow Transplantation. 2018.
@article{098718dc13a14a48b3725993a60edced,
title = "Plerixafor Plus Granulocyte Colony-Stimulating Factor for Patients with Non-Hodgkin Lymphoma and Multiple Myeloma: Long-Term Follow-Up Report",
abstract = "The purpose of this report is to analyze long-term clinical outcomes of patients exposed to plerixafor plus granulocyte colony-stimulating factor (G-CSF) for stem cell mobilization. This was a study of patients with non-Hodgkin lymphoma (NHL; n = 167) and multiple myeloma (MM; n = 163) who were enrolled in the long-term follow-up of 2 pivotal phase III studies (NCT00741325 and NCT00741780) of 240 µg/kg plerixafor plus 10 µg/kg G-CSF, or placebo plus 10 µg/kg G-CSF to mobilize and collect CD34+ cells for autologous hematopoietic stem cell transplantation. Overall survival (OS) and progression-free survival (PFS) were evaluated over a 5-year period following the first dose of plerixafor or placebo. The probability of OS was not significantly different in patients with NHL or MM treated with plerixafor or placebo (NHL: 64{\%}; 95{\%} confidence interval [CI], 56{\%} to 71{\%} versus 56{\%}; 95{\%} CI, 44{\%} to 67{\%}, respectively; MM: 64{\%}; 95{\%} CI, 54{\%} to 72{\%} versus 64{\%}; 95{\%} CI, 53{\%} to 73{\%}, respectively). In addition, there was no statistically significant difference in the probability of PFS over 5 years between treatment groups in patients with NHL (50{\%}; 95{\%} CI, 44{\%} to 67{\%} for plerixafor versus 43{\%}; 95{\%} CI, 31{\%} to 54{\%} for placebo) or those with MM (17{\%}; 95{\%} CI, 10{\%} to 24{\%} for plerixafor versus 30{\%}; 95{\%} CI, 21{\%} to 40{\%} for placebo). In this long-term follow-up study, the addition of plerixafor to G-CSF for stem cell mobilization did not affect 5-year survival in patients with NHL or patients with MM.",
keywords = "Long-term follow-up, Multiple myeloma, Non-Hodgkin lymphoma, Plerixafor, Stem cell mobilization",
author = "Micallef, {Ivana N.} and Stiff, {Patrick J.} and Nademanee, {Auayporn P.} and Richard Maziarz and Horwitz, {Mitchell E.} and Stadtmauer, {Edward A.} and Kaufman, {Jonathan L.} and McCarty, {John M.} and Rita Vargo and Cheverton, {Peter D.} and Martin Struijs and Brian Bolwell and DiPersio, {John F.}",
year = "2018",
month = "1",
day = "1",
doi = "10.1016/j.bbmt.2018.01.039",
language = "English (US)",
journal = "Biology of Blood and Marrow Transplantation",
issn = "1083-8791",
publisher = "Elsevier Inc.",

}

TY - JOUR

T1 - Plerixafor Plus Granulocyte Colony-Stimulating Factor for Patients with Non-Hodgkin Lymphoma and Multiple Myeloma

T2 - Long-Term Follow-Up Report

AU - Micallef, Ivana N.

AU - Stiff, Patrick J.

AU - Nademanee, Auayporn P.

AU - Maziarz, Richard

AU - Horwitz, Mitchell E.

AU - Stadtmauer, Edward A.

AU - Kaufman, Jonathan L.

AU - McCarty, John M.

AU - Vargo, Rita

AU - Cheverton, Peter D.

AU - Struijs, Martin

AU - Bolwell, Brian

AU - DiPersio, John F.

PY - 2018/1/1

Y1 - 2018/1/1

N2 - The purpose of this report is to analyze long-term clinical outcomes of patients exposed to plerixafor plus granulocyte colony-stimulating factor (G-CSF) for stem cell mobilization. This was a study of patients with non-Hodgkin lymphoma (NHL; n = 167) and multiple myeloma (MM; n = 163) who were enrolled in the long-term follow-up of 2 pivotal phase III studies (NCT00741325 and NCT00741780) of 240 µg/kg plerixafor plus 10 µg/kg G-CSF, or placebo plus 10 µg/kg G-CSF to mobilize and collect CD34+ cells for autologous hematopoietic stem cell transplantation. Overall survival (OS) and progression-free survival (PFS) were evaluated over a 5-year period following the first dose of plerixafor or placebo. The probability of OS was not significantly different in patients with NHL or MM treated with plerixafor or placebo (NHL: 64%; 95% confidence interval [CI], 56% to 71% versus 56%; 95% CI, 44% to 67%, respectively; MM: 64%; 95% CI, 54% to 72% versus 64%; 95% CI, 53% to 73%, respectively). In addition, there was no statistically significant difference in the probability of PFS over 5 years between treatment groups in patients with NHL (50%; 95% CI, 44% to 67% for plerixafor versus 43%; 95% CI, 31% to 54% for placebo) or those with MM (17%; 95% CI, 10% to 24% for plerixafor versus 30%; 95% CI, 21% to 40% for placebo). In this long-term follow-up study, the addition of plerixafor to G-CSF for stem cell mobilization did not affect 5-year survival in patients with NHL or patients with MM.

AB - The purpose of this report is to analyze long-term clinical outcomes of patients exposed to plerixafor plus granulocyte colony-stimulating factor (G-CSF) for stem cell mobilization. This was a study of patients with non-Hodgkin lymphoma (NHL; n = 167) and multiple myeloma (MM; n = 163) who were enrolled in the long-term follow-up of 2 pivotal phase III studies (NCT00741325 and NCT00741780) of 240 µg/kg plerixafor plus 10 µg/kg G-CSF, or placebo plus 10 µg/kg G-CSF to mobilize and collect CD34+ cells for autologous hematopoietic stem cell transplantation. Overall survival (OS) and progression-free survival (PFS) were evaluated over a 5-year period following the first dose of plerixafor or placebo. The probability of OS was not significantly different in patients with NHL or MM treated with plerixafor or placebo (NHL: 64%; 95% confidence interval [CI], 56% to 71% versus 56%; 95% CI, 44% to 67%, respectively; MM: 64%; 95% CI, 54% to 72% versus 64%; 95% CI, 53% to 73%, respectively). In addition, there was no statistically significant difference in the probability of PFS over 5 years between treatment groups in patients with NHL (50%; 95% CI, 44% to 67% for plerixafor versus 43%; 95% CI, 31% to 54% for placebo) or those with MM (17%; 95% CI, 10% to 24% for plerixafor versus 30%; 95% CI, 21% to 40% for placebo). In this long-term follow-up study, the addition of plerixafor to G-CSF for stem cell mobilization did not affect 5-year survival in patients with NHL or patients with MM.

KW - Long-term follow-up

KW - Multiple myeloma

KW - Non-Hodgkin lymphoma

KW - Plerixafor

KW - Stem cell mobilization

UR - http://www.scopus.com/inward/record.url?scp=85044348244&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85044348244&partnerID=8YFLogxK

U2 - 10.1016/j.bbmt.2018.01.039

DO - 10.1016/j.bbmt.2018.01.039

M3 - Article

C2 - 29410180

AN - SCOPUS:85044348244

JO - Biology of Blood and Marrow Transplantation

JF - Biology of Blood and Marrow Transplantation

SN - 1083-8791

ER -